Trial Profile
A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cancer vaccine NY-ESO-1; Gp100-MART-1 peptides vaccine; Montanide ISA-51
- Indications Malignant melanoma
- Focus Therapeutic Use
- 17 Jan 2023 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 20 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Dec 2021.